Transgene SA Results from Clinical Study of TG4001 in Combination with Avelumab Conference Call Transcript
Hello, and welcome to the Transgene Reports Results from Clinical Study with TG4001. My name is Monique, and I'll be your coordinator for today's event. Please note, this call is being recorded. (Operator Instructions)
I will now hand you over to your host, Lucie Larguier, to begin today's conference. Thank you.
Thank you, Monique, and hello, everyone. So I'm here today on the call with Philippe Archinard, our Chairman and CEO; as well as Maud Bradley, our Chief Medical Officer. And we're very happy to be discussing with you the promising results that we obtained with TG4001 in combination with avelumab in our exploratory Phase Ib/II trial.
Before I turn over the call to Philippe, I'd like to remind everyone that today's discussion contains forward-looking statements, which are subject to numerous risks and uncertainties. So we would also like to remind you that this call is being recorded and that it will be available on our website.
The webcast can be
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
